Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943875 · ClinicalTrials.gov registry record · Phase 4
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
A Phase 4 study of Human Papilloma Virus and Immunization, sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- Phase 4
- Development phase
- 767
- Enrollment target
- 1
- Study location
NCT03943875: Active Phase 4 study of Human Papilloma Virus and Immunization, sponsored by The University of Texas Medical Branch, Galveston.
NCT03943875 is a Phase 4 study of Human Papilloma Virus and Immunization that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 767 participants, below the 8,422-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943875, a Phase 4 study of Human Papilloma Virus and Immunization, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 767 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Primary Outcome
Yes/No for seroconversion, defined as changing from seronegative (no detectable antibodies) to seropositive (antibodies at or exceeding natural immunity levels) to HPV type 6, measured as % of participants who seroconvert
Conditions Studied
Interventions
- BIOLOGICAL 9-valent HPV vaccine, 3 doses standard timing
- BIOLOGICAL 9-valent HPV vaccine, 2 dose efficacy
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
What the registry record for NCT03943875 still lists
NCT03943875 is an interventional study that assigns participants to a tested intervention. The registered 767 participants enrollment target is mid-sized for trials with a published cap, below the 8,422-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 2 interventions - of which 9-valent HPV vaccine, 3 doses standard timing is the first listed.
NCT03943875 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03943875 about?
NCT03943875 is a clinical study titled "GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose". The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
What is the current status of trial NCT03943875?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 767 participants. The study started on 2019-06-17. Estimated completion is 2026-03-01.
What conditions does trial NCT03943875 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Immunization, Efficacy.
What interventions are being tested in trial NCT03943875?
The interventions under investigation include: 9-valent HPV vaccine, 3 doses standard timing (BIOLOGICAL), 9-valent HPV vaccine, 2 dose efficacy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03943875?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943875 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03943875's enrollment target sits among peer trials
767 12th of 39 higher than 28 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI